Cargando…
Systems thinking in medicine and new drug discovery. Volume one /
Total Quality Management (TQM) and systems thinking are being used to improve all aspects of human health. This first book in a two-volume set details how the healthcare community is working with patients and their caregivers to improve healthcare and reduce its costs. Systems-based thinking encoura...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Newcastle upon Tyne :
Cambridge Scholars Publishing,
2018.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBSCO_on1079759542 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 181220s2018 enka ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d YDX |d OCLCO |d EBLCP |d OCLCA |d UKMGB |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d ELBRO |d OCLCQ |d OCLCO |d K6U |d OCLCQ |d OCLCO | ||
| 015 | |a GBB902419 |2 bnb | ||
| 016 | 7 | |a 019193424 |2 Uk | |
| 020 | |a 9781527523661 |q (electronic bk.) | ||
| 020 | |a 1527523667 |q (electronic bk.) | ||
| 020 | |z 1527506096 | ||
| 020 | |z 9781527506091 | ||
| 029 | 1 | |a UKMGB |b 019193424 | |
| 035 | |a (OCoLC)1079759542 | ||
| 037 | |a 9781527523661 |b Cambridge Scholars Publishing | ||
| 050 | 4 | |a RM301.25 |b .S65 2018 v.1eb | |
| 060 | 4 | |a QV 745 |b SM642s 2018 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.1/9 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Smith, Robert E., |d 1951- |e author. | |
| 245 | 1 | 0 | |a Systems thinking in medicine and new drug discovery. |n Volume one / |c by Robert E. Smith. |
| 264 | 1 | |a Newcastle upon Tyne : |b Cambridge Scholars Publishing, |c 2018. | |
| 264 | 4 | |c ©2018 | |
| 300 | |a 1 online resource (xv, 616 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Intro; Contents; Preface; Chapter One; 1.1 Introduction; 1.2 Reductionist Thinking and DNA; 1.3 Systems Thinking; 1.3.1 Definition and the importance of change; 1.3.2 Misconceptions that are clarified by systems thinking; 1.3.3 Characteristics of systems thinking; 1.3.4 The roots of systems thinking; 1.3.5 Autopoiesis and Gaia; 1.3.6 Systems view of autopoiesis and stem cells; 1.3.7 The importance of networks in life; 1.3.8 Genetics and systems thinking; 1.3.9 Nonlinearity and rhythms in living systems; 1.3.10 The -omics, from genomics to personal -omics | |
| 505 | 8 | |a 1.3.11 A multidimensional, non-linear view of diseases1.3.12 Drugs that bind to multiple targets; 1.3.13 Modularity of biological networks; 1.3.14 Going beyond genomics and looking for hidden connections; 1.3.15 Tools for understanding metabolism better; 1.3.16 Evidence based medicine and the Critical Path Initiative; 1.3.17 Cancer Genome Characterization Initiative, CGCI; 1.3.18 Systems-based thinking in education, in contrast with reductionist thinking inadvertisements and propaganda; 1.4 More systems thinking is needed; 1.5 Reductionist thinking is still useful; References; Chapter Two | |
| 505 | 8 | |a 2.1 The human ecosystem, holobionts, hologenome and viruses2.2 The widespread existence of microbes in the human body; 2.3 Gut microbiome and the enteric nervous system (ENS; 2.3.1 Composition of the gut micr; 2.3.2 Interactions and communication between the ENS and the rest of the body; 2.3.3 Communication between the gut microbiome, ENS, brain and immune system; 2.3.4 The gut microbiota and ENS comprise an entero endocrine organ; 2.4 The role of the gut microbiome in preventing diseases; 2.5 The role of gut microbiome dysbiosis in causing diseases; 2.5.1 The importance of biodiversity | |
| 505 | 8 | |a 2.5.2 The gut microbiome and inflammation2.5.3 The benefits of vegan and vegetarian diets; 2.5.4 The gut microbiome and cardiovascular diseases; 2.5.5 The role of the gut microbiome in stress, anxiety and neurodegenerative diseases; 2.5.6 The importance of healthy microbiota in obtaining an effective response to vaccines; 2.5.7 The importance of oral health and preventing periodontal disease; 2.6 Factors affecting the composition of the microbiome; 2.7 Viruses are important, too; 2.8 Eukarya in the human microbiome; 2.8.1 Introduction to the microbial eukaryotic cells in the human microbiome | |
| 505 | 8 | |a 2.8.2 Fungi2.8.3 Protozoa and intestinal worms (helminths); References; Chapter Three; 3.1 How new drugs are developed; 3.1.1 Select a Disease; 3.1.2 Select a therapeutic target or phenotype; 3.1.3 Find a lead compound; 3.1.4 Improve the lead compound; 3.1.5 Drug delivery; 3.1.6 Manufacturing and cGMP; 3.1.7 Clinical trials; 3.1.8 Many drugs that were developed and approved had a single therapeutic target; 3.1.9 Combinations of drugs are also used and are being developed; 3.1.10 Some targets are now known to have formerly unexpected biological roles | |
| 520 | |a Total Quality Management (TQM) and systems thinking are being used to improve all aspects of human health. This first book in a two-volume set details how the healthcare community is working with patients and their caregivers to improve healthcare and reduce its costs. Systems-based thinking encourages us to work together to look at the effects of new drugs on entire systems and not just single molecular targets. It also leads us to a better understanding of genetics and epigenetics, as well as the deep ecology of the human body. The healthcare community is developing targeted therapies that s. | ||
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Drug development. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Integrative medicine. | |
| 650 | 0 | |a Human biology. | |
| 650 | 2 | |a Drug Discovery | |
| 650 | 2 | |a Chemistry, Pharmaceutical | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Chimie pharmaceutique. | |
| 650 | 6 | |a Médecine intégrative. | |
| 650 | 6 | |a Biologie humaine. | |
| 650 | 7 | |a Pharmacology. |2 bicssc | |
| 650 | 7 | |a Medical toxicology. |2 bicssc | |
| 650 | 7 | |a Cybernetics & systems theory. |2 bicssc | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Human biology |2 fast | |
| 650 | 7 | |a Integrative medicine |2 fast | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 776 | 0 | 8 | |i Print version: |a Smith, Robert E., 1951- |t Systems thinking in medicine and new drug discovery. Volume one. |d Newcastle upon Tyne : Cambridge Scholars Publishing, 2018 |z 1527506096 |w (OCoLC)1019745668 |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1986600 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5621997 | ||
| 938 | |a EBSCOhost |b EBSC |n 1986600 | ||
| 938 | |a eLibro |b ELBO |n ELB119485 | ||
| 938 | |a YBP Library Services |b YANK |n 15900564 | ||
| 994 | |a 92 |b IZTAP | ||